==== Front
Res Sq
ResearchSquare
Research Square
American Journal Experts

37398327
10.21203/rs.3.rs-2997323/v1
10.21203/rs.3.rs-2997323
preprint
1
Article
Transmembrane Stem Factor Nanodiscs Enhanced Revascularization in a Hind Limb Ischemia Model in Diabetic, Hyperlipidemic Rabbits
Takematsu Eri The University of Texas at Austin

Massidda Miles The University of Texas at Austin

Howe Gretchen The University of Texas Health Science Center at Houston

Goldman Julia The University of Texas Health Science Center at Houston

Felli Patricia The University of Texas Health Science Center at Houston

Mei Lei The University of Texas at Austin

Callahan Gregory The University of Texas at Austin

Sligar Andrew The University of Texas at Austin

Smalling Richard The University of Texas Health Science Center at Houston

Baker Aaron The University of Texas at Austin

Authors’ contributions

E.T. analyzed data and wrote/edited the manuscript. M.M., G.H., J.G., P.F., L.M., G.C., A.D.S. and R.S. performed experiments, data collection and analysis. A.B.B. conceived the original idea, analyzed experiments, and wrote/edited the manuscript.

✉ abbaker@austin.utexas.edu
16 6 2023
rs.3.rs-2997323https://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
nihpp-rs2997323v1.pdf
Therapies to revascularize ischemic tissue have long been a goal for the treatment of vascular disease and other disorders. Therapies using stem cell factor (SCF), also known as a c-Kit ligand, had great promise for treating ischemia for myocardial infarct and stroke, however clinical development for SCF was stopped due to toxic side effects including mast cell activation in patients. We recently developed a novel therapy using a transmembrane form of SCF (tmSCF) delivered in lipid nanodiscs. In previous studies, we demonstrated tmSCF nanodiscs were able to induce revascularization of ischemia limbs in mice and did not activate mast cells. To advance this therapeutic towards clinical application, we tested this therapy in an advanced model of hindlimb ischemia in rabbits with hyperlipidemia and diabetes. This model has therapeutic resistance to angiogenic therapies and maintains long term deficits in recovery from ischemic injury. We treated rabbits with local treatment with tmSCF nanodiscs or control solution delivered locally from an alginate gel delivered into the ischemic limb of the rabbits. After eight weeks, we found significantly higher vascularity in the tmSCF nanodisc-treated group in comparison to alginate treated control as quantified through angiography. Histological analysis also showed a significantly higher number of small and large blood vessels in the ischemic muscles of the tmSCF nanodisc treated group. Importantly, we did not observe inflammation or mast cell activation in the rabbits. Overall, this study supports the therapeutic potential of tmSCF nanodiscs for treating peripheral ischemia.

Peripheral Vascular Disease
Peripheral Ischemia
Therapeutic Angiogenesis
Revascularization
transmembrane stem cell factor
nanodisc
rabbit ischemia model
diabetes
hyperlipidemia
DOD CDMRPW81XWH-16-1-0580 W81XWH-16-1-0582 National Institutes of Health1R01HL141761-01
==== Body
pmcIntroduction

Diabetes mellitus affects approximately 350 million people, leading to the death of an estimated 4.6 million people in the world per year1,2. Diabetes leads to a disturbance of the blood vessel by promoting vascular inflammation and endothelial cell dysfunction3,4. These abnormalities increase the severity of vascular disease in diabetic patients5. As a complication of diabetes, 30 to 40 percent of patients age 50 and older develop peripheral artery disease (PAD)6. Severe PAD increases the risk of non-healing ulcers, pain from intermittent claudication, and worst case for limb amputation. Current standard cares for PAD include physical therapy, medication, and surgical revascularization. Surgical bypass is an important treatment option for sever PAD, however many patients especially elderly patients are not eligible because of their diffusive arterial occlusions, no suitable veins for grafting and comorbidity7. Therapeutic angiogenesis by growth factors or growth factor genes is an appealing strategy to treat ischemia in this context but has been difficult to translate in the clinical setting. Many growth factors/gene therapies have shown promise in preclinical studies for ischemia only to show disappointing results in clinical trials in human patients8–10.

Stem cell factor (SCF) is a hematopoietic cytokine that communicates via the c-Kit receptor (CD117) and is also known as Kit ligand, Steel factor, or mast cell growth factor11. Stem cell factor is produced in cells as a transmembrane protein, which is then enzymatically processed into soluble SCF or a shorter version without the cleavable domain, that remains membrane-bound as transmembrane SCF (tmSCF)12. The activation of c-Kit through SCF signaling is crucial for maintaining hematopoietic stem cells (HSCs) and other progenitor cells in the bone marrow13,14. There are many potential therapeutic applications for SCF, including the enhancement of survival and expansion of HSCs after radiation exposure15,16, providing neuroprotection following a stroke17–19, and aiding the heart’s recovery after myocardial infarction20. In addition, SCF plays a crucial role in controlling mast cell development and activation21,22. Unfortunately, clinical and animal studies of SCF treatment have found induction of mast cell activation and anaphylaxis, significantly restricting its potential for therapeutic use22–26. We recently found that tmSCF delivered in proteoliposomes or lipid nanodiscs was effective in inducing revascularization of ischemic limbs in diabetic and wild type mice but did not lead to mast cell activation27. Thus, tmSCF delivered in nanocarriers may provide therapeutic benefits of soluble SCF without the toxic side effects that limited its usefulness as a therapeutic.

While our previous studies have supported the potential of tmSCF nanodiscs as therapies for ischemia, large animal studies are needed to demonstrate efficacy to support further studies in human trials. For peripheral ischemia, rabbits are typically used as the precursor to human studies for treating PAD due the well-developed musculature of the lower limb. Our group recently developed an optimized rabbit model of hindlimb ischemia that includes hyperlipidemia and diabetes28,29. A major advantage of this model is that it exhibits resistance to angiogenic therapies and longer-term ischemia, similar to human patients, in contrast to health rabbit models that revascularize more quickly and have been found to correlate poorly to outcomes in clinical trials. In this study, we used this advanced rabbit model of limb ischemia to evaluate the efficacy of tmSCF nanodiscs in treating peripheral ischemia. Overall, our results demonstrate that tmSCF nanodiscs improve revascularization in ischemia compared to alginate gel control in a large animal without significant inflammatory reaction.

Methods

Preparation of tmSCF Nanodiscs.

A solution of 50 mM 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was created in chloroform and then evaporated to make a thin film. The POPC was resuspended in a solution of 100 mM sodium deoxycholate using multiple cycles of sonication. The MSP protein (5 mg/mL MSP1D1) was then added to phospholipid solution, and the detergent concentration was adjusted to 40 mM. This construct was then incubated for 15 min at 4°C. To solubilize the membrane protein, tmSCF was incubated in the n-octyl-β-D-glucopyranoside (1% w/v) for 15 min at 4°C. In the separate tube, a solution was created of 1 μg/ml, 1% n-octyl-β-D-glucopyranoside (1% w/v) and 40 mM sodium deoxycholate. The POPC and tmSCF solution were combined for 1 hour at 4°C. The combined solution was then dialysed overnight use a 300K MWCO dialysis membrane. Biobeads (SM-2; Bio-Rad Laboratories, Inc) were then used to remove any residual detergent (Supplemental Fig. 1).

Preparation of Alginate Gels and Crosslinking.

Sterile alginate powder (Sigma) was added to sterile saline to create a 2% w/v solution. The final concentration of tmSCF nanodiscs was adjusted to 50 μg/ml in this 2% alginate solution. To prepare the crosslinker, calcium sulfate was added to sterile saline to create 0.2% w/v solution. Both the alginate solution and the crosslinker were taken up into a 1 ml syringe just before injection (100 μl of each solution for 200 μl total per injection).

Induction of Diabetes in Rabbits.

Studies involving animals were performed with the approval of the University of Texas at Austin and the University of Texas Health Science Center at Houston Institutional Animal Care and Use Committees (IACUCs), the Animal Care and Use Review Office (ACURO) of the United States Army Medical Research and Materiel Command Office of Research Protections, and in accordance with NIH guidelines for animal care. The studies performed were in accordance with ARRIVE guidelines. New Zealand rabbits were transitioned from standard alfalfa chow to a 0.1% cholesterol diet over the course of five days. After two weeks on the 0.1% cholesterol diet, rabbits were induced with diabetes using an intravenous alloxan injection. After sedating the rabbits, a bassline blood glucose measurement was attained. Alloxan (100 mg/kg) was injected through an IV into the rabbit at flow rate of 1 ml/min for eight minutes using a syringe pump. Blood glucose levels were monitored closely for 12 hours after the injection. A successful induction of diabetes was determined if the rabbit’s blood glucose level remained over 150 mg/dl prior to insulin administration.

Hind limb Ischemia Surgery and Treatments.

To induce ischemia in the hind limb of New Zealand rabbits, a longitudinal incision was made in the skin over the femoral artery. The femoral artery was exposed using blunt dissection. One percent lidocaine was applied to the area to reduce nerve irritation and promote vasodilation. Continued blunt dissection was used to expose the entire length of the femoral artery and branches including the inferior epigastric, deep femoral, lateral circumflex, and superficial epigastric arteries. The tissue was kept moistened with saline to avoid damage. The femoral artery was then carefully separated from vein and nerve. The femoral artery was then ligated with 4.0 silk sutures, cut, and excised. Two weeks after hind limb ischemia surgery, ten syringes containing 100 μl of alginate with treatment and 100 μl of calcium sulfate crosslinker were prepared for intramuscular injection (200 μl total volume of injection). Treatments included tmSCF nanodiscs in alginate and an alginate-only control.

Angiography Quantification.

Angiograms were quantified using grid analysis techniques with ImageJ Software. Briefly, brightness and contrast were adjusted to better visualize vessels. A grid overlay of 100 pixels per square was used for foot quantification and 750 pixels per square was used for the thigh vasculature quantification. The multi-point tool was used to count intersections between the grid and vessels. To access the carotid artery, an incision was made just lateral to the trachea. Blunt dissection was used to expose the carotid artery and separate it from the jugular vein and vagus nerve. Ligatures were placed at the proximal and distal ends of the carotid artery. The distal end was tied off and a ligaloop was placed at the proximal end. A wire insertion tool was then inserted into the artery. Using the tool, a guidewire was fed into the artery to the aortic bifurcation in the descending aorta. The insertion tool was then removed and a 3F pigtail angiographic catheter was placed over the wire and advanced 2 cm proximal to the aortic bifurcation. Nitroglycerine and lidocaine were given to increase vasodilation. Contrast media was injected through the catheter using an automated angiographic injector. Angiography was performed before femoral ligation, after femoral ligation, and before sacrifice at week 10.

Statistical Analysis.

All results are shown as mean ± standard error of the mean. Comparisons between only two groups were performed using a 2-tailed Student’s t-test. Differences were considered significant at p < 0.05. Multiple comparisons between groups were analyzed by 2-way ANOVA followed by a Tukey post-hoc test. A 2-tailed probability value < 0.05 was considered statistically significant.

Results

Transmembrane SCF nanodiscs enhance revascularization of the ischemic thigh muscles of diabetic, hyperlipidemic rabbits.

Rabbits were given a high fat diet for four weeks and were induced to develop diabetes two weeks prior to surgery for inducing unilateral limb ischemia as described previously28,29. Angiograms were taken before and immediately after the surgery to assess the induction of ischemia in the limbs (Supplemental Fig. 2). The rabbits were then allowed to recover for two weeks to avoid treatment during the acute healing phase of recovery29. The rabbits were given ten injections of alginate with or without the tmSCF nanodiscs and recovery was assess using angiography after 10 weeks (Fig. 1A; Supplemental Fig. 2). Vessel grid intersection counts showed significant vasculature increase for the tmSCF nanodisc group compared to the alginate control (Fig. 1B). When ratioed to the contralateral control limb at week 10, the tmSCF nanodisc group significantly improved recovery compared to the alginate control (Fig. 1C). A ratio was also taken of the grid intersections counted in the ischemic thigh at week 10 to the intersections counted in the ischemic thigh before hind limb surgery. The results show a significant increase in vascularity for the tmSCF nanodisc group in comparison to the control group (Fig. 1D). A new vessel formation is indicated by tortuosity (corkscrew like morphology), which was also counted to assess angiogenic capacity of tmSCF nanodiscs. The results also showed a significant increase in tmSCF nanodisc group in comparison to control. (Fig. 1E).

Transmembrane SCF nanodiscs enhance revascularization of the ischemic calf and foot of diabetic, hyperlipidemic rabbits.

Postoperative angiogram showed the most severe ischemia is the area of the foot and calf muscles (Supplemental Fig. 2). Ten weeks after the operation, robust vascular network formation were observed at the foot of the tmSCF nanodiscs treated group while almost few or no blood vessels was observed in the control group by angiography (Fig. 2A). Quantitative analysis on vessel count showed a significantly higher blood vessel numbers in tmSCF nanodisc group in comparison to the control (Fig. 2B). Similarly, significantly higher ratio of vascular count at the ischemic calf and foot when ratioed to the contralateral control at week 10 (Fig. 2C). A ratio of vessel counts at the ischemic thigh at week 10 to the vessel counts before surgery also demonstrated the effectiveness of the tmSCF nanodisc treatment (Fig. 2D).

Histological analysis confirmed increased vascularity in tmSCF nanodisc treated leg of rabbits with diabetes and hyperlipidemia.

We next performed a histological analysis on biopsies from the ischemic muscle of the rabbits. PECAM immunostaining was used to count small and large vessels formation (Fig. 3A). Significantly more small vessels and large vessels were confirmed with tmSCF nanodisc treatment, indicating that tmSCF nanodiscs induced both angiogenesis and arteriogenesis in the rabbit ischemia model (Fig. 3B). Importantly, no signs of inflammation were was found on the H&E staining of thigh and calf muscle tissues.

Discussion

Stem cell factor is a therapeutic protein with many potential uses for treating disease. Unfortunately, its use has been severely limited by toxic effects that were observed in animal studies and human clinical trials22–26. Managing ischemia in diabetic individuals has presented continuing challenges in the clinical setting, particularly for those undergoing bypass operations or percutaneous procedures30,31 where diabetic patients have worse outcomes and reduced benefits from therapy and interventions. Our previous work demonstrated that tmSCF nanodiscs enhance revascularization in healthy and diabetic mice32. In this work, we evaluated the efficacy of tmSCF embedded in nanodiscs for therapeutic angiogenesis using an optimized rabbit model of hindlimb ischemia with diabetes and hyperlipidemia28,29. Angiography of the thigh and calf muscle treated with tmSCF nanodiscs showed significantly higher numbers of functional blood vessels and new vessels. Histological analysis on PECAM staining and H&E staining also demonstrated significantly higher numbers of small and large vessel formations compared control, indicating that tmSCF nanodiscs support both angiogenesis and arteriogenesis. The findings are particularly significant given the rabbit model’s resistance to angiogenesis and longer-term ischemia28,29. Finally, we did not observe any signs of mast cell activation on histological analysis, consistent with our prior studies in mice27.

Prior studies have explored the use of many treatments in rabbits and other large animals for treating peripheral ischemia and ischemia wounds33,34. A lack of uniformity in the techniques employed for performing and analyzing preclinical hindlimb ischemia models in rabbits makes it difficult to directly compare with other studies. In addition, the majority of prior studies have also used healthy rabbits, which have more rapid recovery from ischemia and responsiveness to angiogenic treatments. Overall, the improvement in revascularization observed in our research using a diseased rabbit model is comparable or superior to earlier studies that utilized healthy rabbit models of hindlimb ischemia to assess protein therapeutics35–57, cell therapies58–62, or gene therapies55,63–75. Consequently, this work supports that tmSCF nanodiscs would have potential as a therapeutic for ischemia, even in the context of therapeutic resistance as would be found in many human patients that have hyperlipidemia and diabetes.

Acknowledgements

The authors gratefully acknowledge funding through the DOD CDMRP (W81XWH-16-1-0580; W81XWH-16-1-0582) and the National Institutes of Health (1R01HL141761-01) to ABB.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Figure 1 Transmembrane SCF nanodiscs enhance revascularization in the thigh of diabetic, hyperlipidemic rabbits with hindlimb ischemia.

(A) Angiograms of the thighs of the rabbits at week 10. The control limb is shown on the right and the limb with the ligated femoral artery is on the left. (B) Quantification of vessel grid intersections counted in the ischemic thigh at the model endpoint. The vessels are counted as number of intersections with an overlayed grid. (C) Relative vascularity of the ischemic thigh ratioed to the contralateral control thigh at the model endpoint. (D) Relative vascularity of the ischemic thigh ratioed to the thigh at day 1 prior to ligation. (E) Quantification of new vessels counted in the ischemic thigh at the model endpoint. *p < 0.05 vs. alginate; **p < 0.01 vs. alginate. (n=3).

Figure 2 tmSCFND enhances revascularization in the calf and foot of diabetic, hyperlipidemic rabbits with hindlimb ischemia.

(A) Angiograms of the lower limb of the rabbits at week 10. (B) Quantification of vessels counted in the ischemic calf and foot at the model endpoint. The vessels are counted as number of intersections with an overlayed grid. (C) Relative vascularity of the ischemic limb ratioed to the contralateral control limb at the model endpoint. (D) Relative vascularity of the ischemic calf and foot ratioed to the calf and foot at day 1 prior to ligation. *p < 0.05 versus alginate; **p < 0.05 versus alginate (n=3).

Figure 3 Histological analysis of vascularization of calf treated by tmSCF nanodiscs.

(A) Upper: H&E staining analysis of biopsies from the ischemic hind limbs of rabbits. Bottom: PECAM staining analysis of biopsies from the ischemic hind limbs of rabbits. Scale bar = 100 μm. (B) Left: Quantification of small vessels counted in the ischemic calf at week 10. Right: Quantification of arterioles vessels counted in the ischemic calf at week 10. *p < 0.05 versus alginate group (n = 3).

Competing interests

The authors (ET and ABB) have patented the technology presented in this manuscript. The other authors (MM, GH, JG, PF, LM, GC, ADS, and RS) on the study do not have competing interests.

Ethics approval and consent to participate

Studies involving animals were performed with the approval of the University of Texas at Austin and the UTHealth Science Center at Houston Institutional Animal Care and Use Committee (IACUC), the Animal Care and Use Review Office (ACURO) of The United States Army Medical Research and Materiel Command Office of Research Protections, and in accordance with NIH guidelines for animal care.

Consent for publication

Not applicable.
==== Refs
References

1. Liang J , Wu Y-L , Chen B-J , Zhang W , Tanaka Y , Sugiyama H . The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related Diseases. International Journal of Biological Sciences. 2013;9 :435–443. doi: 10.7150/ijbs.6087 23678293
2. Futrega K , King M , Lott WB , Doran MR . Treating the whole not the hole: necessary coupling of technologies for diabetic foot ulcer treatment. Trends in Molecular Medicine. 2014;20 :137–142. doi: 10.1016/j.molmed.2013.12.004 24485902
3. Rajendran P , Rengarajan T , Thangavel J , Nishigaki Y , Sakthisekaran D , Sethi G , Nishigaki I . The vascular endothelium and human diseases. International journal of biological sciences. 2013;9 :1057–1069. doi: 10.7150/ijbs.7502 24250251
4. Avogaro A , Albiero M , Menegazzo L , de Kreutzenberg S , Fadini GP . Endothelial Dysfunction in Diabetes. The role of reparatory mechanisms. 2011;34 :S285–S290. doi: 10.2337/dc11-s239 %J Diabetes Care
5. Thiruvoipati T , Kielhorn CE , Armstrong EJ . Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World journal of diabetes. 2015;6 :961–969. doi: 10.4239/wjd.v6.i7.961 26185603
6. Frank J. Tursi CW , and Yost Mary . Essential Keys To Diagnosing And Treating PAD In Patients With Diabetes. Podiatry Today. 2017;30 :12–17.
7. Chang R. Na M , Steven Wang M , Robert S . Kirsner M , and Daniel G . Federman M . The Elderly and Peripheral Arterial Disease. In: Consultant 360; Volume 19 - Number 7 - July 2011.
8. Simons M , Ware JA . Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov. 2003;2 :863–871. doi: 10.1038/nrd1226 14668807
9. Cooke JP , Meng S . Vascular Regeneration in Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020;40 :1627–1634. doi: 10.1161/ATVBAHA.120.312862 32434408
10. Annex BH . Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol. 2013;10 :387–396. doi: 10.1038/nrcardio.2013.70 23670612
11. Broudy VC . Stem Cell Factor and Hematopoiesis. Blood. 1997;90 :1345–1364. doi: 10.1182/blood.V90.4.1345 9269751
12. Lennartsson J , Ronnstrand L . Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92 :1619–1649. doi: 10.1152/physrev.00046.2011 23073628
13. Ding L , Saunders TL , Enikolopov G , Morrison SJ . Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481 :457–462. doi: 10.1038/nature10783 22281595
14. Li CL , Johnson GR . Stem cell factor enhances the survival but not the self-renewal of murine hematopoietic long-term repopulating cells. Blood. 1994;84 :408–414.7517713
15. Gardner RV , Oliver P , Astle CM . Stem cell factor improves the repopulating ability of primitive hematopoietic stem cells after sublethal irradiation (and, to a lesser extent) after bone marrow transplantation in mice. Stem Cells. 1998;16 :112–119. doi: 10.1002/stem.160112 9554035
16. Zsebo KM , Smith KA , Hartley CA , Greenblatt M , Cooke K , Rich W , McNiece IK . Radioprotection of mice by recombinant rat stem cell factor. Proc Natl Acad Sci U S A. 1992;89 :9464–9468. doi: 10.1073/pnas.89.20.9464 1384054
17. Zhao LR , Piao CS , Murikinati SR , Gonzalez-Toledo ME . The role of stem cell factor and granulocyte-colony stimulating factor in treatment of stroke. Recent Pat CNS Drug Discov. 2013;8 :2–12. doi: 10.2174/1574889811308010002 23173646
18. Ping S , Qiu X , Kyle M , Hughes K , Longo J , Zhao L-R . Stem cell factor and granulocyte colony-stimulating factor promote brain repair and improve cognitive function through VEGF-A in a mouse model of CADASIL. Neurobiology of Disease. 2019;132 :104561. doi: 10.1016/j.nbd.2019.104561 31376480
19. Bath PMW , Sprigg N , England T . Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database of Systematic Reviews. 2013. doi: 10.1002/14651858.CD005207.pub4
20. Yaniz-Galende E , Chen J , Chemaly E , Liang L , Hulot JS , McCollum L , Arias T , Fuster V , Zsebo KM , Hajjar RJ . Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res. 2012;111 :1434–1445. doi: 10.1161/CIRCRESAHA.111.263830 22931954
21. Galli SJ , Iemura A , Garlick DS , Gamba-Vitalo C , Zsebo KM , Andrews RG . Reversible expansion of primate mast cell populations in vivo by stem cell factor. J Clin Invest. 1993;91 :148–152. doi: 10.1172/JCI116164 7678600
22. Taylor AM , Galli SJ , Coleman JW . Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells in vitro and in vivo: dependence of the in vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents. Immunology. 1995;86 :427–433.8550081
23. Costa JJ , Demetri GD , Harrist TJ , Dvorak AM , Hayes DF , Merica EA , Menchaca DM , Gringeri AJ , Schwartz LB , Galli SJ . Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med. 1996;183 :2681–2686. doi: 10.1084/jem.183.6.2681 8676090
24. Da Silva CA , Reber L , Frossard N . Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol. 2006;20 :21–39. doi: 10.1111/j.1472-8206.2005.00390.x 16448392
25. Wershil BK , Tsai M , Geissler EN , Zsebo KM , Galli SJ . The rat c-kit ligand, stem cell factor, induces c-kit receptor-dependent mouse mast cell activation in vivo. Evidence that signaling through the c-kit receptor can induce expression of cellular function. J Exp Med. 1992;175 :245–255. doi: 10.1084/jem.175.1.245 1370530
26. Frangogiannis NG , Perrard JL , Mendoza LH , Burns AR , Lindsey ML , Ballantyne CM , Michael LH , Smith CW , Entman ML . Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation. 1998;98 :687–698. doi: 10.1161/01.cir.98.7.687 9715862
27. Takematsu E , Massidda M , Auster J , Chen PC , Im B , Srinath S , Canga S , Singh A , Majid M , Sherman M , Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation. Nat Commun. 2022;13 :2497. doi: 10.1038/s41467-022-30103-2 35523773
28. Sligar AD , Howe G , Goldman J , Felli P , Gómez-Hernández A , Takematsu E , Veith A , Shubh D , Riley WJ , Singeetham R , Syndecan-4 Proteoliposomes Enhance Revascularization in a Rabbit Hind Limb Ischemia Model of Peripheral Ischemia. Biorxiv. 2022;https://www.biorxiv.org/content/10.1101/2022.09.21.508898v1.
29. Sligar AD , Howe G , Goldman J , Felli P , Karanam V , Smalling RW , Baker AB . Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits. J Vis Exp. 2019. doi: 10.3791/58964
30. Fitridge R , Pena G , Mills JL . The patient presenting with chronic limb-threatening ischaemia. Does diabetes influence presentation, limb outcomes and survival? Diabetes Metab Res Rev. 2019:e3242. doi: 10.1002/dmrr.3242 31867854
31. Takahara M , Iida O , Kohsaka S , Soga Y , Fujihara M , Shinke T , Amano T , Ikari Y , J EVT , investigators JP . Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases. Cardiovasc Diabetol. 2019;18 :155. doi: 10.1186/s12933-019-0955-5 31730004
32. Takematsu E , Massidda M , Auster J , Chen P-C , Im B , Srinath S , Canga S , Singh A , Majid M , Sherman M , Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation. Nature Communications. 2022;13 :2497. doi: 10.1038/s41467-022-30103-2
33. Annex BH , Cooke JP . New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease. Circ Res. 2021;128 :1944–1957. doi: 10.1161/CIRCRESAHA.121.318266 34110899
34. Veith AP , Henderson K , Spencer A , Sligar AD , Baker AB . Therapeutic strategies for enhancing angiogenesis in wound healing. Adv Drug Deliv Rev. 2019;146 :97–125. doi: 10.1016/j.addr.2018.09.010 30267742
35. Witzenbichler B , Asahara T , Murohara T , Silver M , Spyridopoulos I , Magner M , Principe N , Kearney M , Hu JS , Isner JM . Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol. 1998;153 :381–394. doi: 10.1016/S0002-9440(10)65582-4 9708799
36. Taniyama Y , Morishita R , Aoki M , Nakagami H , Yamamoto K , Yamazaki K , Matsumoto K , Nakamura T , Kaneda Y , Ogihara T . Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001;8 :181–189. doi: 10.1038/sj.gt.3301379 11313789
37. Takeshita S , Weir L , Chen D , Zheng LP , Riessen R , Bauters C , Symes JF , Ferrara N , Isner JM . Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun. 1996;227 :628–635. doi: 10.1006/bbrc.1996.1556 8878563
38. Pu LQ , Sniderman AD , Brassard R , Lachapelle KJ , Graham AM , Lisbona R , Symes JF . Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation. 1993;88 :208–215. doi: 10.1161/01.cir.88.1.208 8319335
39. Morishita R , Nakamura S , Hayashi S , Taniyama Y , Moriguchi A , Nagano T , Taiji M , Noguchi H , Takeshita S , Matsumoto K , Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension. 1999;33 :1379–1384. doi: 10.1161/01.hyp.33.6.1379 10373220
40. Li M , Liu C , Bin J , Wang Y , Chen J , Xiu J , Pei J , Lai Y , Chen D , Fan C , Mutant hypoxia inducible factor-1alpha improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle. Microvasc Res. 2011;81 :26–33. doi: 10.1016/j.mvr.2010.09.008 20937289
41. Karatzas A , Katsanos K , Lilis I , Papadaki H , Kitrou P , Lecht S , Marcinkiewicz C , Siablis D , Lelkes PI , Lazarovici P , NGF promotes hemodynamic recovery in a rabbit hindlimb ischemic model through trkA- and VEGFR2-dependent pathways. J Cardiovasc Pharmacol. 2013;62 :270–277. doi: 10.1097/FJC.0b013e3182982de7 23644989
42. Hopkins SP , Bulgrin JP , Sims RL , Bowman B , Donovan DL , Schmidt SP . Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia. J Vasc Surg. 1998;27 :886–894; discussion 895. doi: 10.1016/s0741-5214(98)70269-1 9620141
43. Fabre JE , Rivard A , Magner M , Silver M , Isner JM . Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 1999;99 :3043–3049. doi: 10.1161/01.cir.99.23.3043 10368123
44. Chung YI , Kim SK , Lee YK , Park SJ , Cho KO , Yuk SH , Tae G , Kim YH . Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex. J Control Release. 2010;143 :282–289. doi: 10.1016/j.jconrel.2010.01.010 20093158
45. Nitta N , Nitta-Seko A , Sonoda A , Watanabe S , Tsuchiya K , Murata K , Tabata Y . Vascular regeneration by pinpoint delivery of growth factors using a microcatheter reservoir system in a rabbit hind-limb ischemia model. Exp Ther Med. 2012;4 :201–204. doi: 10.3892/etm.2012.574 23139710
46. Doi K , Ikeda T , Marui A , Kushibiki T , Arai Y , Hirose K , Soga Y , Iwakura A , Ueyama K , Yamahara K , Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia. Heart Vessels. 2007;22 :104–108. doi: 10.1007/s00380-006-0934-0 17390205
47. Wafai R , Tudor EM , Angus JA , Wright CE . Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind limb ischemia. J Vasc Res. 2009;46 :45–54. doi: 10.1159/000139132 18552506
48. Lebherz C , von Degenfeld G , Karl A , Pfosser A , Raake P , Pachmayr F , Scholz D , Kupatt C , Boekstegers P . Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factor retroinfusion. Endothelium. 2003;10 :257–265. doi: 10.1080/10623320390246432 14660086
49. Seko A , Nitta N , Sonoda A , Ohta S , Takahashi M , Murata K , Tabata Y . Vascular regeneration by repeated infusions of basic fibroblast growth factor in a rabbit model of hind-limb ischemia. AJR Am J Roentgenol. 2009;192 :W306–310. doi: 10.2214/AJR.07.4013 19457794
50. Kondoh K , Koyama H , Miyata T , Takato T , Hamada H , Shigematsu H . Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. Cardiovasc Res. 2004;61 :132–142. doi: 10.1016/j.cardiores.2003.10.003 14732210
51. Hosaka A , Koyama H , Kushibiki T , Tabata Y , Nishiyama N , Miyata T , Shigematsu H , Takato T , Nagawa H . Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation. 2004;110 :3322–3328. doi: 10.1161/01.CIR.0000147779.17602.18 15520306
52. Li J , Wei Y , Liu K , Yuan C , Tang Y , Quan Q , Chen P , Wang W , Hu H , Yang L . Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model. Microvasc Res. 2010;80 :10–17. doi: 10.1016/j.mvr.2009.12.002 20045007
53. Lederman RJ , Mendelsohn FO , Anderson RD , Saucedo JF , Tenaglia AN , Hermiller JB , Hillegass WB , Rocha-Singh K , Moon TE , Whitehouse MJ , Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359 :2053–2058. doi: 10.1016/s0140-6736(02)08937-7 12086757
54. Simons M , Annex BH , Laham RJ , Kleiman N , Henry T , Dauerman H , Udelson JE , Gervino EV , Pike M , Whitehouse MJ , Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105 :788–793. doi: 10.1161/hc0802.104407 11854116
55. Gowdak LH , Poliakova L , Wang X , Kovesdi I , Fishbein KW , Zacheo A , Palumbo R , Straino S , Emanueli C , Marrocco-Trischitta M , Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation. 2000;102 :565–571. doi: 10.1161/01.cir.102.5.565 10920070
56. Cao R , Brakenhielm E , Pawliuk R , Wariaro D , Post MJ , Wahlberg E , Leboulch P , Cao Y . Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9 :604–613. doi: 10.1038/nm848 12669032
57. Takeshita S , Zheng LP , Brogi E , Kearney M , Pu LQ , Bunting S , Ferrara N , Symes JF , Isner JM . Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93 :662–670. doi: 10.1172/JCI117018 7509344
58. Chua K , Lim FP , Lee VKM , Phan TT , Tai BC , Tan YK . Cord Lining Mesenchymal Stem Cells Have a Modest Positive Effect on Angiogenesis in Hindlimb Ischemia. Front Cell Dev Biol. 2020;8 :596170. doi: 10.3389/fcell.2020.596170 33763413
59. Mikami S , Nakashima A , Nakagawa K , Maruhashi T , Iwamoto Y , Kajikawa M , Matsumoto T , Kihara Y , Chayama K , Noma K , Autologous bone-marrow mesenchymal stem cell implantation and endothelial function in a rabbit ischemic limb model. PLoS One. 2013;8 :e67739. doi: 10.1371/journal.pone.0067739 23861797
60. Kim MS , Lee CS , Hur J , Cho HJ , Jun SI , Kim TY , Lee SW , Suh JW , Park KW , Lee HY , Priming with angiopoietin-1 augments the vasculogenic potential of the peripheral blood stem cells mobilized with granulocyte colony-stimulating factor through a novel Tie2/Ets-1 pathway. Circulation. 2009;120 :2240–2250. doi: 10.1161/CIRCULATIONAHA.109.856815 19917886
61. Fan CL , Gao PJ , Che ZQ , Liu JJ , Wei J , Zhu DL . Therapeutic neovascularization by autologous transplantation with expanded endothelial progenitor cells from peripheral blood into ischemic hind limbs. Acta Pharmacol Sin. 2005;26 :1069–1075. doi: 10.1111/j.1745-7254.2005.00168.x 16115373
62. Vaughan EE , Liew A , Mashayekhi K , Dockery P , McDermott J , Kealy B , Flynn A , Duffy A , Coleman C , O’Regan A , Pretreatment of endothelial progenitor cells with osteopontin enhances cell therapy for peripheral vascular disease. Cell Transplant. 2012;21 :1095–1107. doi: 10.3727/096368911X623880 22304991
63. Pyun WB , Hahn W , Kim DS , Yoo WS , Lee SD , Won JH , Rho BS , Park ZY , Kim JM , Kim S . Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010;17 :1442–1452. doi: 10.1038/gt.2010.101 20668482
64. Tokunaga N , Nagaya N , Shirai M , Tanaka E , Ishibashi-Ueda H , Harada-Shiba M , Kanda M , Ito T , Shimizu W , Tabata Y , Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: benefits of a novel nonviral vector, gelatin. Circulation. 2004;109 :526–531. doi: 10.1161/01.CIR.0000109700.81266.32 14732745
65. Vincent KA , Shyu KG , Luo Y , Magner M , Tio RA , Jiang C , Goldberg MA , Akita GY , Gregory RJ , Isner JM . Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation. 2000;102 :2255–2261. doi: 10.1161/01.cir.102.18.2255 11056102
66. Shyu KG , Manor O , Magner M , Yancopoulos GD , Isner JM . Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation. 1998;98 :2081–2087. doi: 10.1161/01.cir.98.19.2081 9808608
67. Kobayashi K , Kondo T , Inoue N , Aoki M , Mizuno M , Komori K , Yoshida J , Murohara T . Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis. Arterioscler Thromb Vasc Biol. 2006;26 :1465–1472. doi: 10.1161/01.ATV.0000223865.64812.26 16645159
68. Pinkenburg O , Pfosser A , Hinkel R , Bottcher M , Dinges C , Lebherz C , Sultana S , Enssle J , El-Aouni C , Buning H , Recombinant adeno-associated virus-based gene transfer of cathelicidin induces therapeutic neovascularization preferentially via potent collateral growth. Hum Gene Ther. 2009;20 :159–167. doi: 10.1089/hum.2007.178 20377367
69. Chen F , Tan Z , Dong CY , Chen X , Guo SF . Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs. Acta Pharmacol Sin. 2007;28 :493–502. doi: 10.1111/j.1745-7254.2007.00527.x 17376288
70. Zhang C , Wang KZ , Qiang H , Tang YL , Li Q , Li M , Dang XQ . Angiopoiesis and bone regeneration via co-expression of the hVEGF and hBMP genes from an adeno-associated viral vector in vitro and in vivo. Acta Pharmacol Sin. 2010;31 :821–830. doi: 10.1038/aps.2010.67 20581855
71. Dai Q , Huang J , Klitzman B , Dong C , Goldschmidt-Clermont PJ , March KL , Rokovich J , Johnstone B , Rebar EJ , Spratt SK , Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation. 2004;110 :2467–2475. doi: 10.1161/01.CIR.0000145139.53840.49 15477407
72. Jiang H , Zhang T , Sun X . Vascular endothelial growth factor gene delivery by magnetic DNA nanospheres ameliorates limb ischemia in rabbits. J Surg Res. 2005;126 :48–54. doi: 10.1016/j.jss.2005.01.005 15916974
73. Cui K , Zhou X , Luo J , Feng J , Zheng M , Huang D , Jiang J , Chen X , Wei Y , Li J , Dual gene transfer of bFGF and PDGF in a single plasmid for the treatment of myocardial infarction. Exp Ther Med. 2014;7 :691–696. doi: 10.3892/etm.2014.1485 24520269
74. Ohara N , Koyama H , Miyata T , Hamada H , Miyatake SI , Akimoto M , Shigematsu H . Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia. Gene Ther. 2001;8 :837–845. doi: 10.1038/sj.gt.3301475 11423931
75. Nishikage S , Koyama H , Miyata T , Ishii S , Hamada H , Shigematsu H . In vivo electroporation enhances plasmid-based gene transfer of basic fibroblast growth factor for the treatment of ischemic limb. J Surg Res. 2004;120 :37–46. doi: 10.1016/j.jss.2003.12.016 15172188